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To determine the efficacy and safety of thrombolytic
therapy for prosthetic valve thrombosis, a composite
series of 41 patients who received either streptokinase
or urokinase intravenously for this disorder were ana-
lyzed. The series comprised 3 patients treated at Rhode
Island Hospital and 38 previously reported on. Short-
term success was achieved in 32 patients (78%). Pros-
thetic valve thrombosis recurred in seven (22%) of the
successfully treated patients, four of whom were re-
treated with thrombolytic therapy. A favorable clinical
outcome was observed in each.
Prosthetic cardiac valve thrombosis is a serious and poten-
tially lethal complication. Its incidence ranges from I to 6%
in the aortic and mitral valve positions (1-3), to as high as
20% in the tricuspid position (1,4,5) . Reoperation with re-
placement or debridement has been the customary treatment
for this disorder. Operative therapy, however, is encum-
bered by the technical difficulties of a second thoracotomy,
often performed under urgent circumstances. Reported mor-
tality rates after valve replacement or debridement for pros-
thetic valve thrombosis range between 8 and 42% (4,6-10).
Thrombolytic therapy has been advocated as a potential,
nonsurgical alternative for the treatment of prosthetic valve
thrombosis . The precise role of thrombolytic therapy for
prosthetic valve thrombosis, however. is not well defined .
Available information regarding such therapy has been lim-
ited to isolated reports. To enable a more meaningful as-
sessment. we compiled 38 reported cases of this therapy,
in addition to the three patients treated at our institution , to
create a composite series.
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Fever and venipuncture bleeding were the most fre-
quent side effects. Systemic embolization occurred in 4
(15%) of 26 patients with either aortic or mitral pros-
thetic valve thrombosis. None of these latter patients
experienced a permanent neurologic or circulatory def-
icit. It is concluded that thrombolytic therapy is of value
in the treatment of prosthetic valve thrombosis.
(J Am Coil Cardiol 1987;9:592-8)
Illustrative Cases
Case 1
A 36 year old woman underwent repair of a ventricular
septal defect at age 15. During repair, the septal leaflet of
the tricuspid valve was detached . The ventricular septal
defect was closed primarily and the leaflet reapposed to the
anulus . She did well thereafter, until age 34, when she noted
episodes of palpitation and fatigue . Cardiac catheterization
revealed significant tricuspid regurgitation. She underwent
tricuspid valve replacement with a 31 mm St. Jude pros-
thesis . Her hospital course was uncomplicated and she was
discharged on anticoagulation with warfarin . She did well
for 2 years until warfarin administration was discontinued
over a 5 week period. Subsequently, she noted increasing
fatigue . Four days before admission , she no longer heard
her usual prosthetic valve sounds. Her fatigue and malaise
progressed and, after several epi sodes of near syncope. she
was admitted to the hospital .
Clinical features. Blood pressure was 130/80 mm Hg,
pulse 110 beats/min , respiratory rate 20/min. Prosthetic valve
sounds were absent. A faint systolic murmur was noted at
the right sternal border. An echocardiogram demonstrated
absent movement of the prosthetic discs. Fluoroscopically,
the discs appeared immobile and partially open. A 7F NIH
catheter was then advanced to the right atrium by way of a
femoral vein. A 5F Swan-Ganz catheter. introduced into
the right internal jugular vein. was successfully passed across
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Table 1. Data in Three Cases of Prosthetic Valve Thrombus Before and After Treatment With Streptokinase
Tricuspid Valve Mitral Value
Right atrial pressure (mm Hg)
Pulmonary capillary wedge pressure (mm Hg)
Transprosthetic valve gradient (mm Hg)
Cardiac index (liters/min per rrr')
Valve area (crrr')
Case I Case 2
Pre-SK Post-SK Pre-SK Post-SK
15 6 17 6
12 3 13
1.5 4.9 1.2
0.5 3.8 0.33
Case 3
Pre-SK Post-SK
28 16
18 8
J.3 2.4
0.38 0.93
SK = streptokinase.
15
Figure 1. Case I. Hemodynamic response after the initiation of
intravenous (IV) streptokinase in a patientwith tricuspidprosthetic
valve thrombosis. The elevated mean right atrial (RA) pressure
declines to normal levels over the course of therapy.
Case 2
This 59 year old woman had known carcinoid of the
ileum with liver metastases. After diagnosis in 1979, she
was treated with chemotherapy and did well until 1981,
when she noted shortness of breath and fatigue. Significant
tricuspid regurgitation was confirmed by cardiac catheter-
ization. In December 1981, she underwent tricuspid valve
replacement with a 31 mm St. Jude prosthesis. Recovery
was uneventful and she was discharged on anticoagulation
with warfarin. She did well thereafter with improvement in
strength and functional capacity.
Clinical features. In September 1982, she underwent
elective right heart catheterization. At that time, right atrial
pressure was 7 mm Hg with no V wave suggestive of tri-
cuspid regurgitation. The right ventricular end-diastolic
pressure was 8 mm Hg. There was no gradient across the
tricuspid prosthesis. Fluoroscopy of the prosthesis demon-
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the prosthesis into the right ventricle and simultaneous atrial
and ventricular pressures were obtained. Cardiac output was
obtained by dye dilution. A 12 mm gradient was measured
across the prosthesis with a cardiac index of 1.5 liters/min
per rrr'. The calculated valve area was 0.5 em? (Table I).
Therapy. Streptokinase, 250,000 IV, was infused through
a right atrial catheter over 30 minutes. Over the next 72
hours, the dose was adjusted to 100,000 IV/h. Presence of
a lytic state was demonstrated with determinations of throm-
bin time, fibrinogen and fibrin degradation products. By the
seventh hour of therapy, the prosthetic valve sounds were
audible. At 36 hours, valve sounds could be heard without
a stethoscope from the foot of the bed. At the time of the
audible leaflet click, right atrial pressure had declined to 8
mm Hg (Fig. I). At 72 hours, the right atrial pressure had
fallen to 6 mm Hg from a pretreatment value of 12, and the
infusion was discontinued. When the thrombin time assay
subsequently declined to twice normal, intravenous heparin
therapy was begun.
During therapy, the patient's clinical condition improved
markedly; she no longer complained of fatigue and malaise.
Four days after the cessation of streptokinase, she again
underwent cinefluoroscopy and right heart catheterization.
The prosthetic discs were seen to move through their full
excursion. The diastolic gradient across the prosthesis had
decreased to 3 mm Hg and the cardiac index had risen to
4.91 liters/min per m". The valve area was now calculated
to be 3.8 crrr' (Table I).
Thrombolytic therapy with streptokinase was compli-
cated by hyperpyrexia (39]C) and the appearance of shak-
ing chills 7 hours after the initiation of therapy. MUltiple
cultures of blood and urine were negative. The patient's
temperature returned to normal after the cessation of strep-
tokinase and her clinical course was otherwise uncompli-
cated.
The patient's anticoagulation therapy was changed to oral
warfarin and she was discharged asymptomatic on the 13th
hospital day. She continues to be active and asymptomatic
24 months after therapy.
594 KURZROK ET AL.
THROMBOLYSIS FOR VALVE THROMBOSIS
lACC Vol. 9. No.3
March 1987:592-8
strated normal leaflet motion and no evidence of abnor-
mality.
In late November 1982, she noted the onset of progres-
sive fatigue and dyspnea on exertion. Her usually loud pros-
thetic valve sounds became inaudible. Although she had
allegedly not interrupted or changed her warfarin regimen
before admission, her coagulation tests were normal. Phys-
ical examination confirmed the absence of prosthetic valve
sounds.
At right heart catheterization, cinefluoroscopy demon-
strated the valve to be open with no visible motion of the
leaflets. Using a technique similar to that in Case I, valve
hemodynamics were obtained (Table I). There was a 13
mm Hg diastolic gradient across the prosthesis with a cardiac
index of 1.2 liters/min per m". Valve area was 0.33 em".
Treatment. A streptokinase infusion was begun through
a catheter position in the right atrium; 250,000 IU were
infused over the first 30 minutes followed by 100,000 IU/h
for 72 hours. Coagulation tests confirmed a systemic lytic
effect. Prosthetic sounds could be auscultated at 4 hours of
therapy and could be clearly heard from the bedside by 24
hours. Right atrial pressure was 17 mm Hg before the start
of streptokinase infusion, dropping to 10 mm Hg with the
development of an audible valve click, and to 6 mm Hg by
the termination of drug therapy. When coagulation tests
returned to twice normal, intravenous heparin and oral war-
farin were administered.
Subjective clinical improvement was dramatic with com-
plete abolition of the patient's fatigue, malaise and dyspnea.
Subsequent cinefluoroscopy revealed that the excursion of
the prosthetic valve leaflets was again full and equal.
The patient developed fever (38°C) during the strepto-
kinase infusion without evidence of infection. The fever
lysed with termination of the infusion. She also developed
a fascial compartment syndrome at the site of a prior arterial
puncture. This required fasciotomy but left no permanent
deficit. Follow-up right heart catheterization was not per-
formed.
She was discharged asymptomatic and has continued to
do well at 18 months of follow-up with no symptomatic
limitation of her normal daily activities.
Case 3
A 70 year old white woman underwent mitral valve re-
placement at age 58 because of mitral stenosis. A Bjork-
Shiley valve was placed in the mitral position. She did well
until 10 days before admission, when warfarin was discon-
tinued because of anticipated cataract surgery. Three days
before admission, cataract surgery was performed success-
fully. The patient was advised to restart warfarin 3 days
thereafter. One day before admission, she complained of
malaise and on the morning of admission, she presented to
the hospital in pulmonary edema with anuria.
Clinical features. At the time of admission, the patient
was in acute respiratory distress. Blood pressure was 100/60
mm Hg and heart rate was 110 beats/min. Prosthetic valve
sounds were inaudible. The patient was intubated and re-
ceived assisted ventilation and a continuous intravenous in-
fusion of dopamine and intermittent furosemide.
Emergency cardiac catheterization (Table I) revealed a
pulmonary artery pressure of 75/40 mm Hg, mean pulmo-
nary artery wedge pressure of 28 mm Hg, left ventricular
end-diastolic pressure of 10 mm Hg and mean diastolic
gradient of 18 mm Hg. The cardiac output was 2.1 li-
ters/min. Fluoroscopy of the Bjork-Shiley prosthesis re-
vealed attenuated disc motion.
Therapy. The patient then received an infusion of
streptokinase, 500,000 IU over 30 minutes, followed by a
continuous infusion of 100,000 IU /h. Thirty minutes after
the initiation of the infusion, prosthetic valve sounds were
heard intermittently. At 24 hours after the initiation of
thrombolytic therapy, prosthetic valve sounds were con-
sistently crisp. Pulmonary artery pressure had declined to
65/25 mm Hg, the mean wedge pressure to 16 mm Hg and
left ventricular end-diastolic pressure to 8 mm Hg with a
diastolic gradient of 8 mm Hg. Cardiac output had risen to
4.1 liters/min, with a heart rate of 85 beats/min. Strepto-
kinase was then discontinued and the patient received an
intravenous infusion of heparin while warfarin therapy was
initiated. Twenty hours after the initiation of therapy, the
patient experienced left upper quadrant pain. Computed to-
mographic imaging was compatible with splenic infarction.
At no time did the patient experience any neurologic dis-
turbance, hematuria or limb ischemia.
Results of Composite Series
Summary of reported series (4,11-21). Forty-one pa-
tients who received thrombolytic therapy for prosthetic valve
thrombosis constitute this series (Table 2) (38 cases pre-
viously reported [4,11-21] and the 3 cases reported herein).
Eleven patients were men and 25 were women (5 were not
identified by gender). Mean age was 48 years. Eighteen
prostheses were in the mitral, 8 in the aortic and 15 in the
tricuspid position. Of these prosthetic valves, 9 were Starr-
Edwards, 20 Bjork-Shiley, 7 St. Jude, 3 Kaster-Omnisci-
ence and I Hall-Kaster. One tricuspid prosthesis was not
identified.
Streptokinase was the most commonly used thrombolytic
agent (28 patients). Urokinase was used in II patients, and
both agents in 2 patients. For each streptokinase-treated
patient, a loading dose of 150,000 to 600,000 IU was ad-
ministered over 30 to 60 minutes; it was then continued at
100,000 to 200,000 IU/h for 12 to 112 hours. Urokinase
therapy also included a usual loading dose of 150,000 units
JACC Vo!. 9. No.3
March 1987:592-8
KURZROK ET AL.
THROMBOLYSIS FOR VALVE THROMBOSIS
595
Table 2. Data in 41 Reported Cases of Prosthetic Valve Thrombosis After Treatment With Intravenous Thrombolysis
Duration
First Author Pts/Rx Prosthesis Position Drug Regimen (hours) Outcome Complications
Luluaga ( II ) 111 SE T SK Neutralizing dose, then 72 Successful; DIC asymptomatic Epistaxis, venous
100,000 IU/h for 18 hemorrhage, fever
then 150,000 IU/h
Inberg (12) 1/2 BS T SK 600.000 IU/h for I h, 72 Successful for 3 mo. then Fever, venous
then 100,000 IU/h reocclusion --. Re-Rx --. hemorrhage
success; D/C asymptomatic
Peterffy (13) 3/4 BS T SK Fisher's method (2), 12 to 48 Successful (3); normal disc Fever, confusion
250,000 IU/h for I motion (2); abnormal disc
hour, then I(Xl,OOO motion (I ) --. reocclusion
IU/h (I) --. Re-Rx --. success
Witchitz (14) 12113 BS (2) M SK 500,000 IU/h for 30 12to 96 Initial success (5); recurrence Venous hemorrhage,
SE (3) M minutes, then (2); Re-Rx (I); reoperation hemopericardium,
BS (I) Ao 100,000 IU/h ( I); partial response (I) --. uterine bleeding
SE (I) Ao reoperation: failure (I) --.
reoperation
as (I) M UK 150,000 IU/h for 30 24 to 48 Successful (3); transient
SE (3) M minutes, then success (I) --. reoperation:
SE (2) Ao 75.000 to 150,000 failure (2) --. reoperation
IU/h (I); death (I)
Olson (17) 111 BS M SK 250,000 IU bolus Heroic measures-death
Hellestrand (15) III BS T SK 150,000 IU for I h, 66 Successful, D/C asymptomatic Fever
then 100,000 IU/h
Thorburn (4) 212 BS (I) T SK Successful ( I) --. D/C
'? (I) T asymptomatic; failure ( I)
--. reoperation
Joyce (2) III SJ T UK 5,000 IU/kg bolus, 40 Successful --. Die
then 5,000 iU/kg asymptomatic; pediatric
per h, then 10,000 patient
IU/kg per h
Ledain (16) 10111 BS (2) M SK 500,000 IU for 40 10 Successful (3); reoccluded (I ) Brachiocephalic
OS (2) M min, then 150.000 --. Re-Rx --. improved --. deficit
IU/h surgery
BS (I) M UK 4,SOO IU/kg per h 12 Successful (4); failure ( I) --. Upper limb ischemia
SJ (I) M operation --. death Hemianopsia
SJ (2) Ao
OS (I) Ao
BS (I) Ao SK, Doses as above Improved --. surgery
plg- (successful)
UK
BS (I) M UK-SK Doses as above Successful
Wright (18) III BS M SK 600,000 IU/h 72 Successful Subdural hematoma
Gagnon (21) 111 HK M SK 250,000 IU for I hour. 48 Successful
then 200,000 IU/h
Beeuwsaert 4/4 BS (4) T SK 500,000 lU for I hour, 24-112 Successful (2); successful (I) Retroperitoneal
(19) then 100.000 IU/h --. late reocclusion; hemorrhage
reoperation: failure (I)
Kurzrok 3/3 SJ (2) T SK 250,000 to 500,000 IU 24-72 Successful (3) D/C Fever
(present BS (I) M for 30 min, then asymptomatic Splenic infarct
report) 100,000 IU/h
Ao = aortic; BS = Bjork-Shiley;O/C = discharged; HK = Hall-Kaster;M = mitral; OS = Kaster-Omniscience; pIg-UK = plasminogen-associated
urokinase; Pts = number of patients; Rx = number of treatments; Re-Rx = retreatrnent: SE = Starr-Edwards; SJ = SI. Jude; SK = streptokinase;
T = tricuspid; UK = urokinase.
over 30 tninutes followed by 75,000 to 150,000 IU/h over tained in that they remained asymptomatic and did not re-
the next 24 to 48 hours. quire operative intervention during follow-up, which ranged
Outcome of thrombolysis. Thirty-two (78%) of the 41 from 2 to 60 months. One successfully treated patient under-
patients had a successful outcome (Fig. 2). In 24 patients went subsequent elective valve replacement.
(59% of the initial group), the successful outcome was sus- Seven (27%) of the 32 patients with initial successful
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~ thrombolytic therapy
Yes 8 8 No
Repeat success~
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Sustained succes~
Yes G G No
Figure 2. Outcome of 41 patients (3 in the present study and 38
previously reported on) with prosthetic valve thrombosis (PYT)
who received thrombolytic therapy. *Elective valve replacement
in one patient.
treatment (17% of all treated patients) developed recurrent
thrombosis of their prosthesis during the follow-up period.
Three patients had immediate operative valve replacement.
Four patients were retreated with a thrombolytic agent. Re-
treatment in each of these four patients was successful,
although one underwent subsequent elective valve replace-
ment. In the final analysis, 22 (66%) of the 41 initially
treated patients were successfully managed with thrombo-
lytic therapy alone.
During the course ofthrombolytic therapy, three patients
died. One of these patients was moribund at the time throm-
bolytic therapy was initiated; she died 10minutes thereafter.
One patient was improved transiently, then worsened,
underwent emergency surgery and died. The third patient
improved initially but returned 6 months later with rethrom-
bosis and died after reoperation. Thus, the use of throm-
bolytic therapy before or in lieu of immediate reoperation
was associated with an overall mortality of 7%.
Complications. A variety of complications were re-
ported. Fever (temperature 38 to 40°C) was common and
resolved with termination of drug infusion. Hemorrhage at
the site of prior venipuncture was observed frequently. Other
reported complications included hemopericardium (I), uter-
ine bleeding during delivery (I), epistaxis (I), transient
confusion (I), anterior compartment syndrome (I), bra-
chiocephalic arterial embolus (I), upper arm ischemia (I),
hemianopsia (I), subdural hematoma (I), splenic infarction
(I) and retroperitoneal hemorrhage (2). Of26 patients whose
thrombosed prosthetic valve was located in either the mitral
or the aortic position, 4 (15%) had complications that could
have been attributable to embolization of thrombotic rna-
terial from the prosthesis (hemianopsia, brachiocephalic ar-
terial embolus, upper arm ischemia and splenic infarction).
No patient experienced a permanent neurologic or circula-
tory deficit.
Discussion
The incidence of prosthetic valve thrombosis is strongly
correlated with the site of the prosthesis. Thorburn et al.
(4) reported a 20% occlusion rate with tricuspid prostheses
and several investigators (1-3) reported thrombosis occur-
ring in 0.5 to 6.0* of mitral and aortic prostheses (1-3).
Surgical therapy for prosthetic valve thrombosis. Sur-
gical management of prosthetic valve thrombosis, that is,
prosthetic valve replacement or debridement, carries a risk
exceeding that of the original procedure. Of 552 patients
undergoing617 operations for repair or replacementof pros-
thetic valves, Husebye et al. (22) noted an overall operative
mortality rate of 5.9o/c for repeat aortic and 19.6% for repeat
mitral valve replacement. Risk was related to the preoper-
ative functional class and the urgency of the procedure.
Patients in functional classes III and IV had a mortality risk
ranging from 9 to 41%. "Urgent" procedures had a mor-
tality rate of 8 to 20o/c, whereas that for "emergent" pro-
cedures was 37 to 55%. In contrast, patients in functional
classes I and II and those undergoing elective procedures
had a mortality risk of only I to 6%, similar to that of the
original operation.
Several other investigators (23-26) reported mortality
rates in keeping with that of Husebye et al. (22), and con-
firmed the correlation between mortality and advanced func-
tional class at the time of operation. All recommended re-
operation before the occurrence of severe hemodynamic
decompensation.
Results of thrombolytic therapy. Our review indicates
that, in a substantial proportion of cases, thrombolytic ther-
apy may eliminate the need for surgical intervention. Fur-
thermore, in patients who respond only partially to throm-
bolytic therapy, the clinical status may be significantly
improved, thus allowing an elective operative procedure,
with presumably reduced risk. Such therapy appears to re-
duce overall mortality in comparison with surgical mortal-
ity. The survival rate, including late follow-up data, is more
than 90%.
Embolization. A major concern regarding thrombolytic
therapy for prosthetic valve thrombosis is embolization of
thromboticmaterial. Peterffyet al. (5) searched for evidence
of pulmonary embolism (in patients with tricuspid valve
thrombosis) with technetium-labeled microspheres but were
unable to document any significant embolization. Of the 26
patients in our review with either a mitral or aortic pros-
thesis, 4 experienced systemic embolization. All manifes-
tations of embolization disappeared within 2 days. Thus, it
appears that after thrombolytic therapy the majority of pa-
tients with a thrombosed prosthesis in the left side of the
lACC Vol. 9. No. J
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heart will not experience clinically recognizable systemic
embolization. These data are in accordance with observa-
tions of patients receiving urokinase for left ventricular
thrombus after myocardial infarction (27).
Factors influencing outcome. Failure of thrombolytic
therapy to alleviate valve obstruction may be due to the
presence of an organized ingrowth of pannus which was
observed in some patients who required surgical therapy
(3.19.28). Peterffy et al. (5) treated two excised, throm-
bosed prostheses in a saline bath containing streptokinase
at physiologic concentrations. Before immersion, there was
a combination of fresh red clot and older, as well as or-
ganized, white-gray pannus on both disc and struts. After
treatment, the red clot h-d disappeared but the white-gray
pannus remained. Motility of the disc was improved, but
not normalized.
The elapsed time from onset of thromrosis to thrombo-
lytic therapy may influence outcome. Thorburn et al. (4)
noted that thrombolytic therapy was successful in only one
of their two patients; both patients had symptoms suggestive
of prosthetic thrombosis for greater than 6 months. They
suggested that treatment must be instituted before organi-
zation and fibrosis of the thrombus occurs. On the other
hand, a recent report (21) described successful thrombolysis
of a mitral prosthesis in which thrombus formation had been
present for more than 6 months.
Conclusions. Overall, thrombolytic therapy with or
without subsequent surgical intervention appears to be an
effective, yet relatively safe mode of therapy. Intravenous
thrombolytic therapy relieves prosthetic valve thrombosis
in the majorityof cases. Patientselection is important. Those
patients with a reasonably short history of prosthetic valve
thrombosis will obtain the best results. Either streptokinase
or urokinase may be used. Longer duration of treatment.
48 to 72 hours, does not appear to incur additional mortality
and may increase the likelihood of success. Incomplete res-
olution after treatment would predict a poorer long-term
result and such patients may benefit from early, elective
reoperation. Although embolic phenomena have been minor
and relatively infrequent, the judgment to employ throm-
bolytic therapy for prostheses in the left side of the heart
has to be individualized.
Addendum
Ledain et al. (29) recently published an update of their
previously reported (16) experience with thrombolytic ther-
apy of thrombosed prosthetic valves. They have now treated
28 occurrenees of prosthetic obstruction in 26 patients. These
prostheses were all left-sided and about evenly distributed
between the mitral and aortic positions. The patients were
treated with either streptokinase. urokinase, or both, suc-
cessively. The results of this group are consistent with their
past experience and our current report. At 6 to 64 months
of follow-up, they have successfully managed 69o/c of ob-
structed prostheses with medical therapy alone and 85% with
a combined medical and surgical approach.
Their conclusions are also consistent with ours: I) Sur-
gical intervention is not necessary after effective throm-
bolytic treatment. 2) Incomplete success with persistent signs
of dysfunction requires reoperation. 3) The choice of a
thrombolytic agent is of no consequence, provided that an
effective lytic effect is achieved. 4) Longer treatment times
may be beneficial. 5) Embolism. although infrequent, is the
major risk. 6) Patient selection is very important and the
decision to usc thrombolytic therapy must be individualized.
Wc acknowledge the secretarial assistance of Christine Abatiello, Teresa
Newton and Mary Ann McHarg in the preparation of this manuscript.
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